Compare BLBD & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLBD | DFTX |
|---|---|---|
| Founded | 1927 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2013 | N/A |
| Metric | BLBD | DFTX |
|---|---|---|
| Price | $53.38 | $18.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $67.20 | $40.25 |
| AVG Volume (30 Days) | 392.7K | ★ 1.4M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,480,099,000.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.15 | $14.62 |
| 52 Week High | $62.90 | $19.62 |
| Indicator | BLBD | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 53.21 |
| Support Level | $49.55 | $16.26 |
| Resistance Level | $58.25 | $18.21 |
| Average True Range (ATR) | 2.03 | 0.95 |
| MACD | -0.95 | 0.06 |
| Stochastic Oscillator | 10.05 | 43.65 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).